123 related articles for article (PubMed ID: 11205317)
1. Technique and feasibility of a dual staining method for estrogen receptors and AgNORs.
Günther L; Hufnagl P
Anal Cell Pathol; 2000; 20(4):151-4. PubMed ID: 11205317
[TBL] [Abstract][Full Text] [Related]
2. Different proliferation patterns in breast cancer: AgNOR measurements in ER-negative and ER-positive tumor cells.
Günther L; Hufnagl P; Winzer KJ; Guski H
Anal Cell Pathol; 2000; 20(4):155-62. PubMed ID: 11205318
[TBL] [Abstract][Full Text] [Related]
3. AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast.
Guski H; Hufnagl P; Kaufmann O; Krause M; Winzer KJ
Anal Quant Cytol Histol; 2000 Jun; 22(3):206-12. PubMed ID: 10872036
[TBL] [Abstract][Full Text] [Related]
4. Vimentin, AgNORs and estrogen-receptor-related protein-29 in breast carcinoma.
Akpolat I; Erekul S; Kobat I; Bacaci K
Tumori; 1995; 81(4):302. PubMed ID: 8540132
[No Abstract] [Full Text] [Related]
5. Nucleolar organizer regions in human breast cancer.
Roller E; Fritz P; Wicherek C; Klumpp B; Lauinger J; Mischlinski A; Wanner B; Schumacher K
Zentralbl Pathol; 1993 Aug; 139(3):195-9. PubMed ID: 8218120
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of silver-stained nucleolar organizer region associated proteins (AgNORs) after wet autoclave pretreatment in breast carcinoma: correlation to tumor stage and long-term survival.
Ofner D; Bier B; Heinrichs S; Berghorn M; Dünser M; Hagemann HA; Langer D; Böcker W; Schmid KW
Breast Cancer Res Treat; 1996; 39(2):165-76. PubMed ID: 8872325
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of AgNORs in breast cancer].
Aubele M; Auer G; Jütting U
Zentralbl Pathol; 1994 Mar; 140(1):55-60. PubMed ID: 7515674
[TBL] [Abstract][Full Text] [Related]
8. Standardized in situ AgNOR analysis in breast pathology: diagnostic and cell kinetic implications.
Bànkfalvi A; Ofner D; Schmid KW; Schmitz KJ; Breukelmann D; Krech R; Böcker W
Pathol Res Pract; 1999; 195(4):219-29. PubMed ID: 10337659
[TBL] [Abstract][Full Text] [Related]
9. AgNORs in breast tumours.
Ceccarelli C; Trerè D; Santini D; Taffurelli M; Chieco P; Derenzini M
Micron; 2000 Apr; 31(2):143-9. PubMed ID: 10588060
[TBL] [Abstract][Full Text] [Related]
10. Argyrophilic nucleolar organizer regions: their value and correlation with clinical prognostic factors in breast carcinoma.
Kumar A; Kushwaha AK; Kumar M; Gupta S
J Surg Oncol; 1997 Jul; 65(3):201-4. PubMed ID: 9236930
[TBL] [Abstract][Full Text] [Related]
11. AgNORs in ductal breast cancer: correlation with ploidy and S-phase fraction by DNA flow cytometry.
Borgiani L; Cogorno P; Oliviero J; Toso F; Gambini G; Tunesi G; Canepa M
Eur J Histochem; 1994; 38(2):171-6. PubMed ID: 7524814
[TBL] [Abstract][Full Text] [Related]
12. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.
Jacobs TW; Prioleau JE; Stillman IE; Schnitt SJ
J Natl Cancer Inst; 1996 Aug; 88(15):1054-9. PubMed ID: 8683636
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of quantitatively measured AgNORs in ductal mammary carcinoma.
Aubele M; Auer G; Jütting U; Falkmer U; Gais P
Anal Quant Cytol Histol; 1994 Jun; 16(3):211-8. PubMed ID: 7522453
[TBL] [Abstract][Full Text] [Related]
14. AgNOR counts and their combination with flow cytometric analyses and clinical parameters as a prognostic indicator in breast carcinoma.
Rzymowska J
Tumori; 1997; 83(6):938-42. PubMed ID: 9526588
[TBL] [Abstract][Full Text] [Related]
15. Modified silver staining of nucleolar organizer regions to improve the accuracy of image analysis.
Orrea SC; Tomasi VH; Schwint AE; Itoiz ME
Biotech Histochem; 2001 Mar; 76(2):67-73. PubMed ID: 11440307
[TBL] [Abstract][Full Text] [Related]
16. In vitro changes of the nuclear AgNORs pattern induced by RNA inhibitors and 5-fluorouracil in human breast cancer cells, MCF-7 and HBC-4.
Furuya Y; Yamamoto K; Kohno N; Hamaoka T; Ono H; Kuroda Y
Cancer Lett; 1998 Dec; 134(1):97-101. PubMed ID: 10381135
[TBL] [Abstract][Full Text] [Related]
17. Nucleolus organizer regions (AgNORs) in ductal mammary carcinoma. Comparison with classifications and prognosis.
Aubele M; Auer G; Gais P; Jütting U; Rodenacker K; Voss A
Pathol Res Pract; 1994 Feb; 190(2):129-37. PubMed ID: 7520163
[TBL] [Abstract][Full Text] [Related]
18. Tumor proliferative fraction in infiltrating duct carcinoma.
Kesari AL; Chellam VG; Nair PP; Madhavan J; Nair P; Nair MK; Pillai MR
Gen Diagn Pathol; 1997 Dec; 143(4):219-24. PubMed ID: 9489954
[TBL] [Abstract][Full Text] [Related]
19. Quantitative cytological assessment of Ki67 and AgNORs using computer-digitized image analysis of four clinicopathological breast lesions.
Zaitoun AM; Ebbs SR
Cytopathology; 2000 Aug; 11(4):243-54. PubMed ID: 10983724
[TBL] [Abstract][Full Text] [Related]
20. [Nucleolus organizer regions in pathomorphologic tumor diagnosis].
Rüschoff J
Veroff Pathol; 1992; 139():1-144. PubMed ID: 1413987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
